Fig. 4

Patient who underwent several treatments for 2 years after symptom onset before combined laser therapy. (yellow) Fourteen months of SD-OCT follow-up with intermittent Aldactone^® treatment. (green) Acetazolamide daily therapy for 30 days of SD-OCT follow-up. (blue) Thirty days of SD-OCT follow-up after aflibercept intravitreous injection. (pink) Seventeen months of SD-OCT follow-up after combined laser therapy (*) with two additional treatments (**)(***), showing SRD resolution in four months. Baseline multimodal imaging on the day of laser therapy (white dashed square): A Near-infrared imaging showing hypereflectance dots within para- and perifoveal areas. B SD-OCT illustrating the SRD in the DSM. C Color fundus retinography. D Autofluorescence showing hyperautofluorescent dots within para- and perifoveal areas and hyperautofluorescent amorphic material inferior to the macula. Multimodal imaging on the last visit (white dashed square): E Near-infrared imaging showing faded hypereflectance dots within para- and perifoveal areas. F SD-OCT illustrating SRD resolution. G Color fundus retinography. H Autofluorescence showing hypoautofluorescent dots within para- and perifoveal areas and small hypoautofluorescent area from previous amorphic material located inferiorly to the macula